An emerging generic drug player committed to providing access to affordable medicines.

Beximco Pharma

Beximco Pharmaceuticals Ltd.

Beximco Pharmaceuticals Ltd (Beximco Pharma) is an emerging generic drug player committed to providing access to affordable medicines. Company’s state-of-the-art manufacturing facilities have been accredited by the regulatory authorities of Australia, European Union, Canada, and Brazil, among others, and it currently focuses on building presence in many emerging and developed markets around the world.

Beximco Pharma is consistently building upon its portfolio and currently producing more than 500 products encompassing broad therapeutic categories and the Company has created strong differentiation by offering a range of high-tech, specialized products which are difficult to imitate.

Requirements: Medical Promotion Executive
Walk-In Interview: Rangpur, Rajshahi, Bogura, Dhaka

Beximco Pharma COO attends WHO’s 2nd World Production Forum.

Beximco Pharma Chief Operating Officer Rabbur Reza participated as a key panelists in the Second World Local Production Forum (WLPF) being held in Hague, Netherlands during 6-8 November, 2023. The World Local Production Forum is an initiative of WHO with the aim of increasing access to medicines and other health technologies. Mr Reza discussed on the evolution of Bangladesh pharma industry and the importance and challenges of achieving sustainable local manufacturing.

Beximco Pharma team led by COO Mr. Rabbur Reza have attended the largest expo on pharmaceuticals, CPhI Worldwide, being held in Barcelona, Spain during 24-26 October 2023

Congratulations to our Quality Circle team on their GOLD award !!!

Beximco Pharma on Forbes’ list of Best Companies in Asia

Beximco Pharma has made it to the list of the top 200 publicly listed companies in the Asia-Pacific region published by Forbes Magazine. 
Mr. Rabbur Reza, COO of the company, received the award in a grand ceremony held on November 21, 2023 in Manila, Philippines. 
The US based Forbes Magazine recently published its "Asia's 200 Best Under A Billion" list which spotlights 200 top-performing publicly listed companies in the Asia-Pacific region with annual sales under US$1 billion. From a universe of over 20,000 small and midsized companies in the region, these 200 Best Under A Billion companies have track records of exceptional corporate performance. This is the 3rd time Beximco Pharma has made it to this list.

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

COM:BEXIMCOPHARMA

Beximco Pharma

Last Close

33.50

22/11 14:00

Market Cap

1.73M

Beta: -

Volume Today

516.64K

Avg: -

Analysis Not Available